These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 16286244)

  • 1. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
    Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
    Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
    Perrotti D; Neviani P
    Br J Cancer; 2006 Oct; 95(7):775-81. PubMed ID: 16953242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
    Samanta AK; Chakraborty SN; Wang Y; Kantarjian H; Sun X; Hood J; Perrotti D; Arlinghaus RB
    Oncogene; 2009 Apr; 28(14):1669-81. PubMed ID: 19234487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
    Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M
    Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
    Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
    Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
    Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
    Ferrari-Amorotti G; Keeshan K; Zattoni M; Guerzoni C; Iotti G; Cattelani S; Donato NJ; Calabretta B
    Blood; 2006 Aug; 108(4):1353-62. PubMed ID: 16670262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
    Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
    Kurzrock R; Talpaz M; Li L; Estrov Z
    Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
    Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
    Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.